MedTrace Logo

Helicobacter Pylori Resistance

NCT05019586 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 185

Last updated 2021-08-25

No results posted yet for this study

Summary

The main goal of the study was to characterize the morbidity, immunological, microbiolical and clinical phenotypes of patients with treated- resistance to Helicobacter pylori (HP) infection, and the effect of triple therapy including the levofloxacin. Control groups were newly diagnosed, previously infected and never infected HP patients

Conditions

  • Helicobacter Pylori Resistance

Interventions

DRUG

levofloxacin, amoxicillin, clarithromycin

Triple therapy of Helicobacter pylori including two antibiotics and a proton inhibitor for 10 days

Sponsors & Collaborators

  • University Hospital of North Norway

    lead OTHER

Principal Investigators

  • Jon Florholmen · Department of Gastroenterology, Norwegian Artic University/Universiuty of Tromsø, Norway

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-15
Primary Completion
2020-07-10
Completion
2020-07-10

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05019586 on ClinicalTrials.gov